Adenosine Receptor Antagonists During Tissue Ablation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Energy-based tissue ablation therapies lead to elevated adenosine concentrations, causing detrimental symptoms such as metastasis, angiogenesis, tumor cell proliferation, vasodilation, cardiac depression, and inhibition of cell-mediated anti-tumor immune responses.
Innovation Solution
Administering adenosine receptor antagonists like 8SPT, MRS1754, MRS1220, MRE3008F20, MRS1523, ATL146e, or their combinations during ablation procedures to block adenosine receptors, thereby preventing or alleviating symptoms associated with elevated adenosine levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If energy-based tissue ablation is performed to eliminate target tissue, then therapeutic effect is improved, but adenosine concentration increases causing harmful effects
Solution Approach 1:
The patent converts the harmful effect of adenosine accumulation during ablation into a beneficial outcome by administering adenosine receptor antagonists. These antagonists block adenosine receptors, preventing adenosine from exerting its harmful effects while allowing the ablation procedure to proceed effectively. This transforms the problematic adenosine accumulation into a manageable condition through pharmacological intervention.
Solution Approach 2:
The patent introduces adenosine receptor antagonists as intermediary substances that mediate between the ablation process and the body's adenosine system. These antagonists act as blockers that prevent adenosine from binding to its receptors, thereby interrupting the harmful signaling pathway without interfering with the ablation therapy itself.
2Productivity
If adenosine accumulates during ablation, then tumor cell elimination is enhanced, but metastasis and angiogenesis are promoted
Solution Approach 1:
The patent applies the blessing in disguise principle by using adenosine receptor antagonists to prevent adenosine from promoting metastasis and angiogenesis. While adenosine accumulation occurs during ablation, the antagonists block its harmful effects, allowing tumor cell elimination to proceed while preventing the development of metastatic disease and abnormal blood vessel formation.
3Reliability
If adenosine levels rise during ablation, then tissue ablation efficacy is improved, but cardiac depression and hypotension occur
Solution Approach 1:
The patent introduces adenosine receptor antagonists as intermediary protective agents that block the harmful cardiac effects of adenosine. These antagonists prevent adenosine from binding to cardiac adenosine receptors, thereby maintaining cardiac function and blood pressure during ablation procedures while allowing the ablation therapy to remain effective.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The administration of adenosine receptor antagonists effectively reduces angiogenesis, tumor cell proliferation, vasodilation, cardiac depression, and low blood pressure, while enhancing cell-mediated anti-tumor immune responses, thereby maximizing the benefits of ablation therapy and minimizing side effects.
Implementation Method 1
the agent binds to one or more adenosine receptors in vivo
Data Source
AI summary
A mammal undergoing an ablation procedure is treated for symptoms associated with adenosine by administering one or more adenosine receptor antagonists to the mammal prior to or during the procedure.